DexCom rises 5.1% after New England Journal of Medicine study supports CGM for type 2 diabetes

What happened

DexCom (DXCM) rose 5.1% on October 15, 2026, after The New England Journal of Medicine published CONNECT trial results showing continuous glucose monitoring benefited adults with type 2 diabetes not on insulin. Reuters and Business Wire reported the trial; Dexcom called the study landmark and said it provided rigorous evidence supporting CGM use in this population. The stock opened 2.4% above the previous close and traded at 1.2 times its 20-day average on the day.

How big was the move

The stock’s 5.1% gain was 2.2 times a typical daily move for this stock and 3.1 percentage points better than the healthcare sector median, which rose 2.0% that day. The S&P 500 rose 0.3%, making this a large, mostly company-specific move that came after publication of the CONNECT trial. Trading volume was 1.2 times its 20-day average, suggesting above-normal investor interest. Over the last five sessions the stock rose 3.9%, while the S&P 500 over five sessions fell 0.3%.

The technical picture

The stock traded 1.6% above its 20-day moving average and 0.3% above its 50-day moving average, with the 50-day average above the 200-day average, a sign of an established uptrend. The stock had been above its 200-day average for 103 consecutive trading days and was 5.3% below the 52-week high. The Relative Strength Index (14 days) was 55, in a neutral range, and volatility was 37% annualized over 60 days, lower than 69% of its own readings over five years. Price momentum showed a rise of 14.4% over three months and 32.5% over one year, the latter 15.9 percentage points ahead of the S&P 500.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $4.97 billion, which grew 15.5% from a year earlier. Diluted earnings per share were $2.53, which rose 75.7% from a year earlier. Gross margin was 62.5% (a year earlier: 58.8%) and operating margin was 22.9% (a year earlier: 16.0%), reflecting improved profitability. Free-cash-flow margin was 28.3% and return on invested capital was 21.6%. The balance sheet showed net debt of 0.2 times EBITDA, and share count over one year decreased by 4.0%.

The stock traded at 34.7 times trailing earnings and 32.9 times expected forward earnings, with a free-cash-flow yield of 4.4%. Its price to trailing earnings was lower than 86% of its own readings over the past five years (five-year median: 89.1 times earnings). PromtFinance scores ranked the company strong on Value (81), Growth (84) and Momentum (86), and Exceptional on Quality (97), with positive Revisions (69) and Stability (73). Those measures portray a company growing revenue and converting it to cash while retaining high quality metrics.

Earnings and analyst expectations

The next report was scheduled for October 29, 2026. The last report, on July 30, 2026, showed earnings per share of $0.70 against $0.61 expected, 14.6% above estimates. That marked five consecutive quarters beating estimates, with the average surprise over the last four reports 11.3% above estimates. The typical two-day reaction after recent reports was unchanged. Fifty-two analysts covered the stock, with a consensus rating of Buy and 81% of ratings Buy or higher. The consensus price target was $95.07, 8.4% above the closing price.

What to watch

• October 29, 2026: next quarterly earnings report date.
• The New England Journal of Medicine CONNECT trial publication, reported by Reuters and Business Wire, and subsequent commentary from guideline bodies.
• Consensus price target of $95.07 versus the closing price.
• Trading volume relative to its 20-day average and any follow-through over the next five trading days.
• Any updates to guidance or NHS/insurance coverage discussions tied to CGM use for adults with type 2 diabetes who are not on insulin.